CSCI vs. XFOR, DYAI, OTLK, CTMX, MIST, PEPG, PRLD, ALVR, RNTX, and IPSC
Should you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include X4 Pharmaceuticals (XFOR), Dyadic International (DYAI), Outlook Therapeutics (OTLK), CytomX Therapeutics (CTMX), Milestone Pharmaceuticals (MIST), PepGen (PEPG), Prelude Therapeutics (PRLD), AlloVir (ALVR), Rein Therapeutics (RNTX), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry.
COSCIENS Biopharma vs.
COSCIENS Biopharma (NASDAQ:CSCI) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.
X4 Pharmaceuticals received 79 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users.
COSCIENS Biopharma has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
X4 Pharmaceuticals has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -428.43%. COSCIENS Biopharma's return on equity of -95.93% beat X4 Pharmaceuticals' return on equity.
X4 Pharmaceuticals has a consensus target price of $2.83, indicating a potential upside of 1,384.98%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than COSCIENS Biopharma.
COSCIENS Biopharma has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks.
0.7% of COSCIENS Biopharma shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 0.1% of COSCIENS Biopharma shares are held by company insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, COSCIENS Biopharma had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for COSCIENS Biopharma and 1 mentions for X4 Pharmaceuticals. COSCIENS Biopharma's average media sentiment score of 0.41 beat X4 Pharmaceuticals' score of 0.00 indicating that COSCIENS Biopharma is being referred to more favorably in the media.
Summary
X4 Pharmaceuticals beats COSCIENS Biopharma on 9 of the 17 factors compared between the two stocks.
Get COSCIENS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COSCIENS Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CSCI) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy CSCI Stock Free CSCI Stock Alerts